Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lymphangioleiomyomatosis.

S R Johnson1

  • 1Division of Therapeutics and Molecular Medicine, University Hospital, Queens Medical Centre, Nottingham NG7 2UH, UK. simon.johnson@nottingham.ac.uk

The European Respiratory Journal
|May 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deformation and Collectivity in Doubly Magic ^{208}Pb.

Physical review letters·2025
Same author

Gamma Decay of the ^{154}Sm Isovector Giant Dipole Resonance: Smekal-Raman Scattering as a Novel Probe of Nuclear Ground-State Deformation.

Physical review letters·2025
Same author

Pulmonary Lymphangioleiomyomatosis originates in the pleural mesothelial cell population.

Medical hypotheses·2020
Same author

Cancer, employment, and American Indians: A participatory action research pilot study.

Rehabilitation counseling bulletin·2019
Same author

Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition.

Journal of scleroderma and related disorders·2018
Same author

The UK guidelines for management and surveillance of Tuberous Sclerosis Complex.

QJM : monthly journal of the Association of Physicians·2018
Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026
Same journal

ERS Statement on ultrasound guided interventions in respiratory disease.

The European respiratory journal·2026
Same journal

When symptoms and resting tests disagree in interstitial lung disease: a selective role for cardiopulmonary exercise testing.

The European respiratory journal·2026
Same journal

Clinical Practice Guideline for the diagnosis of Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency Disorders (CVID) - an ERS Clinical Research Collaboration.

The European respiratory journal·2026
Same journal

SARS-CoV-2 (E)-protein induces rapid TLR2-mediated T cell activation in mouse lungs revealed by intravital lung microscopy.

The European respiratory journal·2026
Same journal

Functional characterization of <b><i>KCNA5</i></b> gene variants linked to pulmonary arterial hypertension.

The European respiratory journal·2026
See all related articles

Lymphangioleiomyomatosis (LAM) is a rare lung disease affecting women, characterized by cysts and respiratory failure. Emerging research suggests rapamycin may offer a new evidence-based treatment for LAM.

Area of Science:

  • Pulmonology
  • Rare Diseases
  • Genetics

Background:

  • Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder affecting the lungs and lymphatics, primarily in women.
  • It presents with progressive pulmonary cysts, pneumothorax, chylous effusions, and respiratory failure, alongside abdominal manifestations like lymphangioleiomyomas and angiomyolipomas.
  • LAM is associated with tuberous sclerosis and characterized by somatic mutations in TSC genes.

Purpose of the Study:

  • To provide a comprehensive overview of Lymphangioleiomyomatosis (LAM).
  • To discuss current diagnostic and treatment strategies for LAM.
  • To highlight recent advancements in understanding LAM's cell biology and potential therapeutic targets.

Main Methods:

  • Review of clinical features, diagnostic criteria, and imaging (CT scans, lung biopsy).

Related Experiment Videos

  • Analysis of treatment approaches for LAM complications and severe disease (hormone therapy, lung transplantation).
  • Exploration of recent cell biology findings, including genetic mutations and the potential role of rapamycin.

    • Main Results:

    • Diagnosis relies on clinical presentation, CT scans, and sometimes lung biopsy.
    • Current treatments focus on managing LAM complications; lung transplantation is the only option for severe cases.
    • Somatic mutations in TSC-related genes are identified in LAM, with rapamycin showing potential to correct cellular abnormalities.

    Conclusions:

    • LAM is a rare, progressive disease primarily affecting women, with significant pulmonary and abdominal manifestations.
    • While current treatments manage symptoms, rapamycin presents a promising avenue for evidence-based therapy in ongoing clinical trials.
    • Understanding the genetic basis of LAM offers hope for improved therapeutic strategies and patient outcomes.